RNA Inhibitor Shows Early Efficacy, Safety in Adults With Mixed Dyslipidemia
Robert Rosenson, MD, discusses original findings from a double-blind, placebo-controlled phase IIb study evaluating the efficacy and safety of investigational ARO-ANG3, a small interfering RNA inhibitor, in adults with mixed dyslipidemia at the American Heart Association annual meeting.
